Loading...

COLL COLLEGIUM PHARMACEUTICAL INC Accounting Changes 8-K Filing

CLLG

CLL

COLLEGIUM PHARMACEUTICAL INC

(COLL)

2023 8-K

Show Summary

Summary

Management Change

Board Expansion

2025 Financial Guidance

Merger Announcement

CEO Appointment

Merger Completion

Earnings Reports

Merger Agreement and Loan A...

FDA Exclusivity Granted

Appointment, Separation Agr...

Annual Meeting Voting Results

Share Repurchase Agreement

Management Change

Earnings Reports

Authorized Generic Agreement

Redemption of Convertible S...

Earnings Reports

Press Release and Investor ...

Share Repurchase Agreement

FDA Exclusivity Grant

Share Repurchase Agreement

Earnings Reports

Earnings Reports

Financial Results Announcement

Material Definitive Agreement

Earnings Reports

Press Release and Share Rep...

External Links:

Collegium Pharmaceutical, Inc. announces that the FDA has granted New Patient Population exclusivity for Nucynta, extending its U.S. exclusivity period.

AI Assistant

COLLEGIUM PHARMACEUTICAL INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.